748,466 Shares in Repligen Corporation $RGEN Acquired by Bamco Inc. NY

Key Points

• Bamco Inc. NY acquired 748,466 Repligen shares worth approximately $102.1 million, giving it a 1.33% stake. Institutional investors and hedge funds collectively own 97.64% of the company.
• Repligen reported quarterly EPS of $0.54, beating estimates by $0.09, while revenue rose 11.9% year over year to $204.13 million. The company issued fiscal 2026 EPS guidance of $2.03–$2.09.
• Analysts maintain a consensus “Buy” rating with an average price target of $166.43, although the stock opened at $180.30 and carries a high valuation, including a P/E ratio near 247.

Bamco Inc. NY bought a new position in Repligen Corporation (NASDAQ:RGEN - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 748,466 shares of the biotechnology company's stock, valued at approximately $102,121,000. Bamco Inc. NY owned 1.33% of Repligen as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. United Capital Financial Advisors LLC acquired a new position in Repligen in the third quarter valued at $368,387,000. Opti Capital Management LP acquired a new stake in Repligen in the 4th quarter worth about $2,399,209,000. Maverick Capital Ltd. purchased a new stake in Repligen in the 1st quarter valued at about $178,946,000. Wasatch Advisors LP purchased a new stake in Repligen in the 1st quarter valued at about $146,513,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company's stock valued at $753,603,000 after acquiring an additional 1,091,683 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Down 0.8%

NASDAQ RGEN opened at $180.30 on Thursday. The stock has a market cap of $10.18 billion, a PE ratio of 246.99, a P/E/G ratio of 3.32 and a beta of 1.03. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73. The business has a 50 day moving average price of $150.11 and a two-hundred day moving average price of $132.51. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter last year, the firm posted $0.26 earnings per share. The business's quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada began coverage on shares of Repligen in a research note on Thursday, May 14th. They set an "outperform" rating and a $160.00 price target on the stock. Benchmark upgraded Repligen from a "hold" rating to a "buy" rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. HSBC cut their target price on Repligen from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Wednesday, June 3rd. Wolfe Research assumed coverage on Repligen in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $145.00 target price on the stock. Finally, Barclays boosted their price target on Repligen from $145.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $166.43.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.60% of the company's stock.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source